NWA
De Nationale Wetenschapsagenda

LymphChip: Developing immunocompetent human organ-on-a-chip models with integrated lymph drainage for drug discovery and testing

The lymphatic system plays a crucial role in our immune system, for example by regulating the immune response to pathogens. Lymphatic dysfunction underlies a multiplicity of diseases, and could determine the effectiveness of therapies, whether drug or stem-cell based. Yet, in the new generation of in-vitro organ models used to study the effect of drugs and therapies without the need for animals, the lymphatic system and the immune cells they transport are notably absent. The fact that the lymphatics of human organs are significantly different from those of animals like mice, and ethical concerns about animal use combine to an urgent need for human-physiologically relevant organotypic models that include human lymph-endothelial and immune cells. In LymphChip, pioneers of the organ-on-chip platform join forces to develop these models for the first time.

Starting from proven stem cell-derived models of three organ systems (heart, intestine, and skin), we will develop innovative combinations of microengineered biomimetic 3D scaffolds, miniaturized interstitial flow models and on-line sensing, integrating primary and stem cell-derived tissues and corresponding tissue lymphatics. We will thus create powerful models for studying tissue homeostasis via fluid transport (for the heart), small molecule and dietary fat transport (intestine) and immune surveillance (for skin and lymph nodes). This will provide unprecedented opportunities for studying human disease in which the lymphatic system is defective by providing personalized, patient-specific immune systems in near-native tissue environments with stromal and immune cell components and real-time measures of function.

Our ambition is to provide game-changing technology to address presently intractable conditions of the immune system using three tissues as exemplars that will lead the way towards the identification of novel pathways for these and other organs while reducing animal use.

Dossiernummer
NWA.1292.19.019
Projectleider
dr. V. Orlova
Hoofdorganisatie
Leids Universitair Medisch Centrum
Programma
Onderzoek op Routes door Consortia 2019
Financieringsinstrument
NWA L1
Status
Lopend
Thema
Ziekten en gezondheid
Consortium
Leiden University Medical Center (LUMC), VU Medical Center (VUMC), Wageningen University and Research, Universiteit Twentse, Technische Universiteit Delft, Universiteit Maastricht, IBA Lifesciences GmbH, TissUse GmbH, Nederlandse Brandwonden Stichting, Dutch Society for the Replacement of Animal Testing (dsRAT,Proefdiervrij), BioEC, Cealus health, IMEC (One Planet), PolyVation, Alveolé, Optics11, hDMT, Ibidi GmbH, AIM Biotech, VSParticle, Amsterdam UMC (AMC), Red Cross Hospital Beverwijk, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Maag Lever Darm Stichting, The University of Melbourne, Ncardia, Roche, Danone Nutricia Research

Onderdeel van route

Wij beantwoorden deze vragen

Welke vragen hopen we met dit project te beantwoorden? Deze vragen zijn gegroepeerd in de volgende clustervragen.